Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features01:24

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
Chronic Obstructive Pulmonary Disease I: Introduction01:23

Chronic Obstructive Pulmonary Disease I: Introduction

Chronic obstructive pulmonary disease is a common, preventable, and treatable respiratory disorder characterized by persistent symptoms and progressive airflow limitation. This limitation results from a combination of small-airway disease (obstructive bronchiolitis) and parenchymal destruction (emphysema), both driven by chronic inflammation from exposure to harmful particles or gases.The disease includes two main pathological entities: emphysema, marked by destruction of alveolar walls and...
Chronic Obstructive Pulmonary Disease II: Emphysema01:23

Chronic Obstructive Pulmonary Disease II: Emphysema

Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.
Chronic Obstructive Pulmonary Disease-I: Introduction01:20

Chronic Obstructive Pulmonary Disease-I: Introduction

Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
Other Pulmonary Disorders01:17

Other Pulmonary Disorders

Respiratory disorders encompass a range of conditions with varying levels of severity. Asthma, marked by chronic airway inflammation and hypersensitivity, is one such condition. It can lead to airway obstruction due to factors like bronchial spasms, mucosal edema, increased mucus secretion, or epithelial damage. Asthma triggers are diverse, ranging from allergens to emotional upset, and treatment focuses on both immediate relief through bronchodilators and long-term inflammation suppression.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Use of Bronchoscopic Cryobiopsy in Evaluating Interstitial Lung Disease: Radiologic Predictors of Diagnostic Yield and Safety.

Mayo Clinic proceedings·2026
Same author

Pulmonary venoocclusive disease/pulmonary capillary hemangiomatosis: Inadequacy of clinico-radiologic features in diagnosis.

Human pathology·2026
Same author

Lung Auscultation for Detecting Interstitial Lung Disease in Patients with Newly Diagnosed Systemic Sclerosis: Retrospective Cohort Study.

Diagnostics (Basel, Switzerland)·2026
Same author

Spontaneous pneumothorax-associated with genetic disorders.

Therapeutic advances in respiratory disease·2026
Same author

Pulmonary Hypertension Associated With Interstitial Lung Disease: State-of-the-Art Review.

The European respiratory journal·2026
Same author

Current diagnosis, epidemiology, and management of interstitial lung abnormalities.

Frontiers in medicine·2026

Related Experiment Video

Updated: Jul 3, 2026

Cigarette Smoke Exposure in Mice using a Whole-Body Inhalation System
06:07

Cigarette Smoke Exposure in Mice using a Whole-Body Inhalation System

Published on: October 22, 2020

Cigarette smoking and diffuse lung disease.

Rajesh R Patel1, Jay H Ryu, Robert Vassallo

  • 1Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA.

Drugs
|July 17, 2008
PubMed
Summary
This summary is machine-generated.

Cigarette smoke causes lung diseases like RB-ILD, DIP, and PLCH. Smoking cessation can improve these conditions, highlighting its role as a primary cause.

More Related Videos

Automated Measurement of Pulmonary Emphysema and Small Airway Remodeling in Cigarette Smoke-exposed Mice
10:37

Automated Measurement of Pulmonary Emphysema and Small Airway Remodeling in Cigarette Smoke-exposed Mice

Published on: January 16, 2015

Isolation of Mouse Respiratory Epithelial Cells and Exposure to Experimental Cigarette Smoke at Air Liquid Interface
10:47

Isolation of Mouse Respiratory Epithelial Cells and Exposure to Experimental Cigarette Smoke at Air Liquid Interface

Published on: February 21, 2011

Related Experiment Videos

Last Updated: Jul 3, 2026

Cigarette Smoke Exposure in Mice using a Whole-Body Inhalation System
06:07

Cigarette Smoke Exposure in Mice using a Whole-Body Inhalation System

Published on: October 22, 2020

Automated Measurement of Pulmonary Emphysema and Small Airway Remodeling in Cigarette Smoke-exposed Mice
10:37

Automated Measurement of Pulmonary Emphysema and Small Airway Remodeling in Cigarette Smoke-exposed Mice

Published on: January 16, 2015

Isolation of Mouse Respiratory Epithelial Cells and Exposure to Experimental Cigarette Smoke at Air Liquid Interface
10:47

Isolation of Mouse Respiratory Epithelial Cells and Exposure to Experimental Cigarette Smoke at Air Liquid Interface

Published on: February 21, 2011

Area of Science:

  • Pulmonology
  • Toxicology
  • Pathology

Background:

  • Cigarette smoke contains over 4000 chemicals, causing respiratory ailments and infections.
  • Smoking is a principal cause of respiratory bronchiolitis-interstitial lung disease (RB-ILD), desquamative interstitial pneumonia (DIP), and pulmonary Langerhans' cell histiocytosis (PLCH).
  • These smoking-related lung diseases can coexist and may improve with smoking cessation.

Purpose of the Study:

  • To review the role of cigarette smoking in diffuse lung diseases.
  • To propose a novel classification of smoking-related lung diseases.
  • To emphasize smoking cessation as a primary therapeutic strategy.

Main Methods:

  • Literature review of clinical and epidemiological data.
  • Analysis of histopathological findings in lung biopsies.
  • Evaluation of the impact of smoking cessation and re-exposure.

Main Results:

  • Strong evidence links cigarette smoke to RB-ILD, DIP, and PLCH.
  • Smoking cessation can lead to disease improvement, and recurrence is seen upon re-exposure.
  • Histopathological changes in these diseases implicate smoking as a common inciting agent.

Conclusions:

  • Cigarette smoking is a primary etiological factor in RB-ILD, DIP, and PLCH.
  • Smoking cessation should be central to managing these diffuse lung diseases.
  • Pharmacotherapy is reserved for selected patients with these smoking-induced lung conditions.